Introduction
The expression of the p210 BCR-ABL fusion protein in hematopoietic stem cells (HSCs) plays an essential role in the pathogenesis of chronic myeloid leukemia (CML) (Era and Witte, 2000) , resulting in the expansion of these cells without impairment of their ability to dierentiate (Kantarjian et al., 1993) . The numbers of all types of blood cells are thus increased in both peripheral blood and bone marrow (BM) of individuals with CML during the so-called`chronic phase (CP)' of the disease. Treatment of aected individuals with interferon (IFN)-a or hydroxyurea (HU), or both, reduces the number of blood cells but it is still dicult that such treatment totally eradicates the BCR ± ABL ± expressing cells (Silver et al., 1999) . The eventual loss of the ability of the malignant clones of CML patients to dierentiate results in progression to the terminal`blast crisis (BC)' stage of the disease, which resembles de novo acute myeloid leukemia (AML). Some patients exhibit an intermediate`accelerated phase (AP)' between the CP and BC stage of CML. Transformation to the BC stage renders CML refractory to treatment including allogeneic BM transplantation. The prognosis of patients in BC is thus poor, with a median survival time of only 3 ± 4 months. Improvement in the overall prognosis for individuals with CML therefore requires both clari®ca-tion of the mechanism of stage progression as well as the ability to predict the probability that a given patient will undergo transformation to BC at a given time.
DNA microarray analysis allows characterization of the expression pro®les of thousands of genes at a time. It should therefore be a suitable approach with which to identify genes that might prove informative for stage diagnosis of CML or that contribute to stage progression (Duggan et al., 1999) . However, a simple comparison of BM mononuclear cells (MNCs) among dierent patients often produces a large number of pseudo-positive results, given that the proportion of leukemic blasts in BM varies markedly among such individuals. If, for example, total MNCs from the BM of patients containing 5 or 90% identical leukemic blasts are compared, DNA microarray analysis would mistakenly suggest that the two individuals suer from distinct disorders. This`population shift' eect is one of the main causes of pseudo-positive results in highthroughput screening. Eective elimination of such pseudo-positive data requires isolation of the leukemic blasts and comparison of the transcriptomes of these puri®ed cells. The character or background of the samples subjected to microarray analysis should be matched as closely as possible, so that they dier only in the parameter under investigation, such as whether the patient has undergone transformation to BC or not. We have proposed that such a microarray approach with highly puri®ed specimens be termed background-matched population (BAMP) screening .
HSCs or pluripotent immature cells that are early descendents of HSCs are the blood cells that are aected in many types of leukemia, including CML, AML and myelodysplastic syndrome (MDS). Thus, the HSC-like fraction would be expected to be a suitable target for BAMP screening of leukemic disorders. Puri®cation and analysis of the HSC-like fraction should allow direct evaluation and comparison of the characteristics of leukemic blasts irrespective of the proportion of blasts in BM. Given that AC133 is one of the most speci®c cell surface markers available for HSCs (Hin et al., 1997) , we have puri®ed AC133-positive cell fractions from individuals with a wide range of hematologic disorders and have stored these fractions for our large-scale genomics project, termed Blast Bank'. Furthermore, DNA microarray analysis with the Blast Bank samples has resulted in the identi®cation of molecular markers that dierentiate MDS from de novo AML .
With the use of Blast Bank samples puri®ed from individuals with CML, we have now identi®ed sets of genes whose expression is dependent on disease stage. Transcriptome pro®ling of the Blast Bank samples also revealed that the blasts of one CP patient exhibited a transcriptome similar to that of blasts from BC patients. Consistent with this observation, control of the white blood cell (WBC) count in the peripheral blood of this CP patient was dicult, despite sustained treatment with HU.
Results and discussion

Transcriptomes of CML blasts
Our Blast Bank is rapidly expanding and currently comprises 192 specimens of AC133 + blasts, including 24 samples derived from individuals with CML. At the timing of microarray experiment, we had a total of 13 (CML samples (derived from seven patients in CP, two patients in AP, and four patients in BC (all in myeloid crisis)) in our Bank, all of which were subjected to expression analysis. BM MNCs of every patient were proved to carry either Ph1 chromosome (judged by karyotype analysis) or the fusion transcript encoding p210 BCR-ABL (judged by reverse-transcription (RT ± PCR)). The healthy control sample from the Blast Bank (a mixture of specimens from healthy volunteers) was also included in the study.
We Biotin-labeled cRNA was then synthesized from each sample and subjected to hybridization with oligonucleotide microarrays representing 3456 human genes. Through our microarray analyses, we had noticed that neither b-actin nor glyceraldehyde 3-phosphate dehydrogenase gene was a reliable internal control, at least, when used a single control gene. The digitized data were, therefore, normalized on the basis of the average spot intensity for each hybridization. Hierarchical clustering analysis of the data resulted in generation of a dendrogram, or`gene tree', in which genes with similar expression pro®les are positioned near each other ( Figure 1a ). The expression level of each gene was assigned a pseudocolor, with high expression represented by red and low expression by green. The gene tree revealed that between *25 and 33% of the genes studied were transcriptionally active in the puri®ed blasts of individuals with CML. Several clusters of genes were active only in the blasts corresponding to a speci®c disease stage or to subgroups of patients at a speci®c stage.
Identi®cation of stage-speci®c genes is potentially of clinical importance, given that it should facilitate stage determination and the design of an optimal therapeutic strategy for each patient. To identify such genes, we calculated the average expression intensity of each gene for the CP, AP, and BC groups and used these data to generate another dendrogram,`average tree' ( Figure  1b ). This average tree has revealed the presence of clusters of genes that are expressed speci®cally in either healthy control, CP, AP, or BC specimens. The genes in these clusters are thus candidates for the CML stage-speci®c molecular markers.
Genes specific to CP
From the average tree shown in Figure 1b , we selected several groups of genes whose expression pro®les were suggestive of biological relevance. The expression of a total of 39 genes (at least in terms of mean expression intensity) was speci®c to CP. The detailed expression pro®les of each of these genes are shown in Figure 2a . The gene showing the highest level of CP-speci®c expression was that for the interferon-induced protein with tetratricopeptide repeats-2 (IFIT-2). The abundance of IFIT-2 transcripts was especially high in ®ve out of the seven samples of CP blasts (CP3 to CP7), but was low or undetectable in the healthy control sample and samples corresponding to the other stages of CML.
IFIT-2 was originally identi®ed by dierential screening in an attempt to isolate IFN-inducible genes (Wathelet et al., 19888) . Although most individuals in CP of CML are treated with IFN, the increased expression of IFIT-2 in the CP blast samples was not attributable to an eect of IFN treatment. Four (CP4 to CP7) of the ®ve patients exhibiting high expression of IFIT-2 were diagnosed with CML on the basis of the BM aspirates that provided the samples for this study, and therefore had not been previously treated for CML. The patient CP3 had once been treated with IFN-a, but the administration of this cytokine was terminated as a result of progression of mental depression, a severe side eect of IFN-a treatment, before the analysed blast sample was obtained.
It remains to be determined whether the expression of IFIT-2 is related to the blast sensitivity to IFN-a. Three (CP5 to CP7) of the ®ve patients with high IFIT-2 expression were treated with IFN-a after sampling of AC133 + cells; two of them (CP6 and CP7) responded well to the treatment, resulting in good control of peripheral blood cell number, whereas patient CP5 underwent BC transformation within a few months of treatment onset.
The genes for type 1 and type 2 receptors for IFN-a, IFN-b, and IFN-o were not signi®cantly expressed in any of the samples analysed in the present study. Expression of the genes for IFN-g receptor 2 (IFNGR2) and for IFN-g, however, was increased in both patients CP6 and CP7 (Figure 2a ). The biological relevance of the overexpression of the genes for the components of this IFN-g autocrine loop remains to be determined.
In addition to IFNGR2, several other genes, including those for LAGE-1 (Lethe et al., 1998) and B melanoma antigen (BAGE) (Boel et al., 1995) , were selectively expressed in CP patients 6 and 7 ( Figure 2a ). Both LAGE-1 and BAGE were identi®ed as a result of screening for melanoma-speci®c antigens that are recognized by cytotoxic T cells. They are known to be expressed in solid tumors but not, with the exception of the testis, in normal tissues. Expression of these two genes in hematopoietic lineages has not previously been demonstrated. As with IFIT-2, the expression of LAGE-1 and BAGE did not appear to correlate with the administration of IFN-a. It remains unknown whether the loss of LAGE-1 or BAGE expression contributes to the escape from immunological surveillance of blast cells in CML and to the transformation from CP to AP or BC stages.
Genes up-regulated in AP or BC
The activated BCR ± ABL tyrosine kinase plays an important role in the pathogenesis of CP in CML. However, the molecular events that trigger the transformation to AP or BC stages remain unclear. It is possible that both transcriptional activation and transcriptional repression contribute to this transformation process. From the average tree shown in Figure 1b , we identi®ed 17 genes that appeared not to be expressed in the AC133 + blasts of healthy control and CP individuals but were transcriptionally active in those of AP or BC patients. The expression pro®les of these genes, including those for DNA damage ± binding protein 1 (DDB1) (Chu and Chang, 1988) and NADH-ubiquinone oxidoreductase 1b subcomplex 8 (NDUFB8) (Loeen et al., 1998) , are shown in Figure 2b .
DDB1 functions in the repair of DNA damage, and loss of its activity is responsible for pathogenesis of complementation group E of xeroderma pigmentosum. A reduction in the stability of DNA as well as various types of chromosomal anomaly are often apparent in blasts from individuals in the advanced stages of CML. The induction of DDB1 expression now detected in the blasts of AP and BC patients may therefore re¯ect an accumulation of DNA damage in these cells. NDUFB8 is a component of a large enzyme complex that Mean expression values for each gene were calculated for CP, AP, and BC stages, and used to generate a dendrogram. The presence of clusters of genes whose expression is speci®c to healthy control, CP, AP, or BC samples is evident contributes to electron transport in mitochondria. Induction of NDUFB8 expression and a consequent increase in the rate of the mitochondrial respiratory reaction in transformed blasts may re¯ect an increased catabolic activity in these cells. Both DDB1 and NDUFB8 were also expressed in the patient CP1, raising the possibility that this individual may have been in the process of transformation to the AP or BC stage.
Genes down-regulated in AP or BC
We next identi®ed nine genes whose expression was reduced in the AC133 + cells of AP or BC patients compared with that in AC133 + cells of healthy individuals or CP patients (Figure 2c ). One such gene was that for the protein inhibitor of activated STAT (signal transducer and activator of transcription) y (PIASy), which belongs to the PIAS family of proteins that also includes PIAS1, PIAS3, PIASxa, and PIASxb (Shuai, 2000) . PIAS1 and PIAS3 bind to and inhibit the activity of STAT1 and STAT3, respectively. Recently, Liu et al. (2001) have revealed that PIASy is also a transcriptional repressor of STAT1. STAT proteins are often hyper-phosphorylated and activated in aected cells from individuals with a variety of leukemias (Gouilleux-Gruart et al., 1997) . Introduction of the BCR ± ABL tyrosine kinase into hematopoietic cell lines results in the activation of STAT proteins (Carlesso et al., 1996) , indicating that these proteins mediate BCR ± ABL signaling. PIASy may therefore counteract the transforming potential of activated STAT proteins in the leukemic blasts of CP patients, and the subsequent disappearance of this protein may result in deregulation of cell growth and stage progression.
Another interesting gene in this group may be that for death-associated protein kinase 3 (DAPK3), or ZIP kinase (Kawai et al., 1998) . DAPK3 homo-dimerizes through its leucine-zipper domain, and subsequent activation of DAPK3 induces apoptotic cell death. Loss of DAPK3 expression may therefore renders the leukemic blasts resistant to physiological apoptotic stimuli, and this may be an important step for the further transformation into AP or BC stages.
Clustering of patients according to gene expression profiles
The dendrograms of the expression of all genes analysed (Figure 1) as well as the expression patterns of CPspeci®c genes (Figure 2a ) both demonstrated that a set of genes was transcriptionally active only in CP patients 6 and 7 (Figure 1a, arrow) , suggesting the existence of subgroups within CP patients. To evaluate statistically the heterogeneity among CP patients, we performed two-way clustering analysis (Alon et al., 1999) on the gene tree shown in Figure 1a . Such analysis generates a dendrogram that groups patients according to the similarity of their gene expression pro®les (Figure 3) . The patients CP6 and CP7 were indeed clustered in the same branch of the dendrogram. Patients CP4 and CP5 were also grouped in the same branch. Two additional clusters of patients were of interest: one comprising two AP patients (#1 and #2) and one BC patient (#1), and one containing one BC patient (#3) and CP patient 1. Indeed, transcription of the AP-or BC-speci®c genes was increased in patient CP1, whereas none of the CPspeci®c genes was expressed at a substantial level in this patient (Figure 2a,b) . The AC133 + blasts of this individual thus exhibit a transcriptome most similar to that of BC blasts. What is the biological relevance of this classi®ca-tion of CML patients based on the results of microarray analysis? Patient CP1 was admitted to hospital with markedly increased WBC (240 300 cells/ ml) and platelet (1 751 000 cells/ml) counts in addition to anemia (hemoglobin concentration, 7.7 g/dl). Treatment with HU resulted in a decrease in WBC and platelet counts (7300 and 712 000 cells/ml, respectively) without the correction of anemia. However, the initial attempt to reduce the dosage of HU (from 1000 to 500 mg/day) resulted in a rapid rebound in WBC count (from 7300 to 150 200 cells/ml). The second attempt at dosage reduction (from 1500 to 1000 mg/day) again failed to maintain the WBC count within the normal range; the count increased from 9160 to 21 030 cells/ml. This clinical history reveals the highly proliferative nature of the leukemic blasts of this patient, which is an unusual characteristic for the CP stage of CML. The similarity of the transcriptome of the blasts from patient CP1 to that of blasts from BC patients suggests that this individual may undergo transformation into AP or BC stage in a relatively short period.
Construction of a novel retroviral vector for conditional expression of an exogenous gene
To con®rm the changes in the expression level of the CML stage-speci®c genes, we performed quantitativè real-time' PCR. The abundance of IFIT-2 and PIASy transcripts was determined relative to that of b-actin mRNA in an extended number of Blast Bank samples (one healthy volunteer, nine patients in CP, ®ve patients in AP and seven patients in BC). Consistent with the results obtained with microarray analysis, the expression of IFIT-2 was marked only in the blasts from CP patients, but was below the level of detection in the blasts from other individuals (Figure 4a) . Similarly, expression of PIASy was greatly reduced in the blasts of AP and BC patients compared with that in blasts from healthy volunteers and CP patients (Figure 4b ). The discrepancy of the PIASy expression levels in the control sample between the array data ( Figure 2c ) and real-time PCR (Figure 4b ) may re¯ect the dierent methods for normalization; array data is normalized on the basis of mean expression value for each hybridization while the data in real-time PCR is on the expression level of b-actin.
Given the possible involvement of PIASy in the STAT-mediated signalings, we next tried to clarify the biological signi®cance of the change in PIASy expression level during the course of CML progression. If PIASy protein has a growth suppressor activity, then the decrease of its expression may allow a deregulated growth of leukemic blasts in the advanced stages of CML. If this is the case, forced expression of PIASy in the CML cells from the BC stage would induce apoptosis of, or restore the dierentiation ability of, the CML blasts. We thus examined the eect of PIASy expression in a human cell line, KCL22, that is derived from a patient in BC of CML.
When characterizing cell clones stably expressing an exogenous gene, it is often dicult to determine whether the phenotype of the transformants arises from the expression of the incorporated gene or from clonal variations within transfected cells. To overcome such ambiguity, here we have constructed a novel retroviral plasmid (pMX-tetOFF), by which a gene of interest can be conditionally expressed in polyclonal cell population through a single round of retroviral infection. The group of J-K. Yee has developed a b-estradioldependent tetracycline repressor (tTAER) (Iida et al., 1996) . Only under the presence of b-estradiol and absence of tetracycline, this protein becomes active and The ratio of the abundance of the target transcripts to that of b-actin mRNA was calculated as 2 n , where n is the C t value for b-actin cDNA minus the C t value of the target cDNA induces the transcription via the tetracycline repressorbinding sequence (tetO). However, either addition of tetracycline or depletion of b-estradiol results in the blockage of the tetO-mediated transcription.
The internal ribosome entry site (ires) elements are known to allow translation of internal cistrons of mRNAs independently from the well-characterized capping-mediated ribosome scanning (Jang et al., 1989) . The ires fragment derived from encephalomyocarditis virus (EMCV) was ligated with the cDNA for blasticidin S-resistant marker protein (BSR) (Izumi et al., 1991) . All of the tTAER and ires-BSR fragments and the tetO sequence were inserted into pMX retroviral vector (Onishi et al., 1996) in this order, generating pMX-tetOFF (Figure 5a, top panel) . When transduced, the long terminal repeat (LTR)-driven RNA should produce the capping site-mediated translation of tTAER as well as the ires-mediated translation of BSR, conferring the transduced cells the resistance against blasticidin-S. Under the presence of tetracycline or absence of b-estradiol, tTAER cannot drive the transcription from the tetO site (middle panel). Removal of tetracycline and addition of b-estradiol, however, should conditionally induce the expression of an exogenous gene (FLAG-tagged PIASy (PIASy-F), in this case) placed downstream of the tetO site (lower panel).
Infection of target cells with the retrovirus generated from pMX-tetOFF containing the PIASy-F cDNA (pMX-tetOFF/PIASy-F) should thus allow blasticidin-S-resistant polyclonal cell population, almost all of which express PIASy-F through a dual-regulation system with tetracycline and b-estradiol. Recombinant retrovirus was generated from pMX-tetOFF or pMXtetOFF/PIASy-F, and was used to infect KCL22 cells which were subsequently cultured under the presence of blasticidin-S and tetracycline. The drug-resistant mass culture of each infection was then transferred to a medium containing blasticidin-S and b-estradiol, but without tetracycline. Total cell lysates as well as anti-FLAG immunoprecipitates were prepared from each fraction, and were probed with anti-FLAG antibody. As expected, PIASy-F was readily detected in the cells infected with MX-tetOFF/PIASy-F under the induction condition (Figure 5b ). It should be noted, however, that a marginal leaky expression of the protein was detectable even under the presence of tetracycline.
PIASy as an inducer of apoptosis
Does the expression of PIASy aect the growth of KCL22 cells? Surprisingly, as shown in the left panel of Figure 6a , growth rate of KCL22 cells was severely retarded only when PIASy-F was induced. In addition, the growth suppression was only marginal in the cells infected with MX-tetOFF/PIASy-F at a non-induced condition. On the contrast, the mock-infected cells grew exponentially irrespective of the culture conditions. Concomitant with these growth properties, the viability of KCL22 cells became rapidly impaired in the PIASy-expressing KCL22 cells, while that of the other KCL22 culture remained healthy (right panel).
Such rapid suppression of cell growth could be the result of an induction of apoptosis or dierentiation into mature blood cells. To clarify the mechanism of growth suppression in KCL22, morphology of the cells maintained at the induction condition for 6 days were analysed by Wright-Giemsa staining. Mock-infected cells under the presence of b-estradiol retained their parental phenotypes; middle-sized cells with basophilic Figure 5 Construction of a dual regulation vector, pMXtetOFF. (a) The cDNA for tTAER, ires-BSR cassette and the tetO fragment were inserted in this order into the retrovirus backbone vector, pMX, to generate pMX-tetOFF. For the expression of PIASy-F, the corresponding cDNA was placed downstream to tetO (top panel). Under the presence of tetracycline (tet) and absence of b-estradiol (est), tTAER can no longer bind to tetO, and therefore the transcription of PIASy-F is suppressed (middle panel). Removal of tetracycline and addition of b-estradiol, however, induce the dimerization of tTAER and its binding to the tetO fragment, leading to the activation of transcription for the PIASy-F gene (bottom panel). (b) After incubation for 24 h under the presence of tetracycline (7) or bestradiol (+), KCL22 cells infected with MX-tetOFF (Mock) or MX-tetOFF/PIASy-F (PIASy) were subjected to solubilization. Total cell lysates (TCL; 10 mg/lane) and the immunoprecipitates with anti-FLAG antibody (aFLAG IP) were then probed with the antibodies to FLAG. The positions of PIASy-F and IgH are indicated by an arrow and an asterisk, respectively, at the right. The positions of molecular weight standards (610 -3 ) are also shown at the left cytoplasm, high nuclear to cytoplasm ratio, and ®ne nuclear structure (Figure 6b, left panel) . In contrast, many cells expressing PIASy-F have undergone apoptotic changes at day 6; shrinkage of cells, condensation and fragmentation of nuclei (right panel). We could not ®nd in these cells the commitment to dierentiation into any speci®c cell lineages.
To con®rm the apoptotic change found in the PIASy-expressing cells, the cells were stained with Annexin-V (BD Biosciences) and propidium iodide (PI), and subjected to¯ow cytometry analysis to detect the translocation of phosphatidylserine (PS) from the inner part to the outer layer of cell membrane, a characteristic feature of apoptosis. As shown in Figure  6c , forced expression of PIASy-F resulted in an increase of apoptosis fraction (PS-positive and PInegative cells) from 6.3% in the uninduced state to 17.0% in the induced state.
BAMP screening with Blast Bank samples from CML patients
Analysis of the Blast Bank samples has provided data of clinical relevance. Previous analysis with MNCs, rather than with AC133 + cells, revealed that CD34 was one of the genes whose expression was most increased in the BC stage (A Miyazato, personal communication). However, this result appears to be pseudopositive, given that analysis of Blast Bank samples demonstrated almost equal expression of CD34 during the course of CML (data not shown). The present study has identi®ed potential molecular markers for each stage of CML. Although DDB1 was identi®ed as a marker for AP or BC, it was also highly expressed in patient CP1. If this latter patient undergoes transformation to AP/BC, the expression level of DDB1 (and possibly that of NDUFB8) might prove useful as a predictor for such transformation. Such predictors may facilitate both the design of treatment strategies targeted to individual CML patients as well as determination of the timing of BM transplantation.
More importantly, our present data has proposed a novel mechanism for stage progression in CML; the change in PIASy expression level. In the AC133 + cells of normal individuals and CP patients, the gene for PIASy was highly expressed while it became decreased along with the stage progression toward BC. Experiments with the KCL22 CML cell line has clearly indicated the growth suppressive nature of PIASy. Since PIASy has been recently demonstrated to function as a STAT1 inhibitor, induction of apoptosis may be attributable to the PIASy regulation of STAT proteins. However, we could not detect activation/phosphorylation of STAT1 in KCL22 cells irrespective of PIASy expression (data not shown). It may be, therefore, still an open question through which mechanism PIASy blocks cell growth of a BC-derived cell line. Tyrosine phosphorylation of p210 BCR-ABL in KCL22 cells was not aected by the induction of PIASy (data not shown).
In conclusion, our microarray analysis with the puri®ed Blast Bank samples was demonstrated to be a highly useful system to identify molecular markers for the various stages of CML as well as to provide insight into the molecular mechanism of transformation.
Materials and methods
Preparation of Blast Bank samples
BM aspirates were obtained from subjects with written informed consent. MNCs were puri®ed from the specimens by Ficoll-Hypaque (Amersham Pharmacia Biotech) density gradient centrifugation, labeled with anti-AC133 MicroBeads (Miltenyi Biotec, Auburn, CA, USA), and subjected to chromatography on a miniMACS magnetic cell separation column (Miltenyi Biotec). The resulting AC133 + cell fractions were divided into portions and stored at 7808C as the Blast Bank samples. AC133 + cells were also puri®ed from BM MNCs of healthy volunteers and mixed for use as a`healthy control' sample. The purity of each sample was con®rmed by Wright-Giemsa staining. When a sucient number of AC133 + cells was obtained, the purity was also evaluated by¯ow cytometric analysis with antibodies to AC133, to CD34, and to CD38 (BD Biosciences, San Jose, CA, USA).
RNA preparation and DNA microarray analysis
Total RNA was extracted from Blast Bank samples by the acid guanidinium method and was subjected to ampli®cation as previously described (Van Gelder et al., 1990) . All samples were ampli®ed twice, and the correlation coecient of DNA microarray data obtained with RNA after the ®rst and the second rounds of ampli®cation was calculated to be 0.93. One microgram of the ampli®ed cRNA was converted to doublestranded cDNA which was then used to prepare biotinlabeled cRNA with the use of the ExpressChip labeling system (Mergen, San Leandro, CA, USA), and was allowed to hybridize with microarrays (HO-1*3; Mergen) that contain oligonucleotides corresponding to a total of 3456 human genes (the gene list on the arrays is available at http:// www.mergen-ltd.com/). The microarrays were then incubated consecutively with streptavidin, with antibodies to streptavidin, and with Cy3-conjugated secondary antibodies (all from Mergen). Detection of hybridization signals and statistical analysis of the digitized data were performed with a GMS 418 array scanner (Aymetrix, Santa Clara, CA, USA) and GeneSpring 3.2.2 software (Silicon Genetics, Redwood, CA, USA), respectively. In the hierarchical clustering analysis, similarity was measured by the standard correlation with a separation ratio of 0.5.
Real-time PCR analysis
Portions of unampli®ed cDNA were subjected to PCR with SYBR Green PCR Core Reagents (PE Applied Biosystems, Foster City, CA, USA). The incorporation of the SYBR Green dye into the PCR products was monitored in real time with an ABI PRISM 7700 sequence detection system (PE Applied Biosystems), thereby allowing determination of the threshold cycle (C t ) at which exponential ampli®cation of PCR products begins. The C t values for cDNAs corresponding to the b-actin gene and target genes were used to calculate the abundance of the target transcripts relative to that of b-actin mRNA. The oligonucleotide primers for PCR were as follows: b-actin cDNA, 5'-CCATCATGAAGTGT-GACGTGG-3' and 5'-GTCCGCCTAGAAGCATTTGCG-the pMX vector. This work was supported in part by a
